

SUBJECT INDEX TO VOLUME 4

Acrivastine	473	anticholinergic/antiserotonergic	
Activating NK receptor.....	142	side effects of	511
NKG2D as	142	as tools for regulating inflammation	81
Adhesion molecules expression.....	84	carcinogenicity/tumorigenicity/mutage-	
inhibition of	84	nicity of	513
Adipose tissue	619	cardiac toxicity of	507,510
classical cytokines in	620	central nervous system side effects of	507
chemokines in	620	classification of	469
hormones in	620	desloratadine as	511
Adjuvants	185	drug interactions of	507
general considerations on mechanisms of		ebastine as	511
action of.....	185	effect of breastfeeding	513,519
routes of delivery of	185	fexofenadine as	511
Ageing	350	hepatotoxicity of	512
immune system in	350	in management of allergic rhinitis	477
Aggrecanase	251	in ocular therapy	481
assay design of	256	in pregnancy	517
characterization of	254	inhibition of mediator released by.....	85
family of	251	loratadine as	511
gene family of	253	mizolastine as	511
inhibition by naturally occurring inhibitors	256	ocular pharmacology of	482
inhibition by synthetic small molecule inhibitors ..	257	other anti-inflammatory effects of.....	86
inhibitors of	251	pharmacological basis for development of	
purification of	252	cardiac adverse effects with	510
Allergic contact dermatitis.....	65	sedating effects of	507
allergenic substances to induced.....	68	skin tests of	517
by allergenic natural products.....	70	symptoms/treatment of overdose of	512
cells implicated in.....	66	use for angioedema	486
flavonoids against.....	73	use for atopic dermatitis	488
<i>in vivo</i> protocols for.....	67	use for contact dermatitis	491
inhibitors of.....	67	use for eosinophilic disorders	491
mediators of.....	66	use for mastocytosis	490
other compounds against	77	use for other disorders	491
phenolics against.....	72	use for urticaria	486
plant extracts against	70	Apoptosis	429,561
study of	67	as modulator of inflammatory response	350
terpenoids against	74	as non-inflammatory form of PCD	561
Allergic ocular disease	481	as regulator of immunologic processes	350
common forms of	481	immune mediated	430
H ₁ antagonists in	482	in autoimmune disease	429
H ₂ antagonists in	483	in autoimmune thyroid disease	434
management of	483	in multiple sclerosis	432
Allergic reactions	81	in rheumatoid arthritis	434
Allergic rhinitis (AR)	477	in systemic lupus erythematosus (SLE)	431
first generation antihistamines in	478	in type 1 diabetes mellitus	432
next generation antihistamines in	479	Apoptotic cell death	383
oral antihistamines in	478	by S100A8/A9/released	383
pathophysiology of	477	in tumor cells	383
second generation antihistamines in	478	induction of	383
treatment strategy for	478	Apoptotic machinery	407
Alzheimer's disease	372	Astemizole	471
Antihistamines	81,465,477,481,486,507,517	Atherosclerosis	283
action mechanism of	465	inflammation in	283
adverse effects of	517	therapeutic target for	283
adverse systemic reactions of	507	Autoimmune disease	334,435
antiallergic effects of	467,478	animal models for	334
		treatment of	435

Autonomic nervous system	627	mediated apoptosis signaling	598
Azelastine	473	Caspase activation	407
Behcet's disease	339	pharmacological modulation of	407
antibiotics in	345	therapeutic approaches leading to	413
antivirals in	345	Caspase inhibition	409
arthritis in	343	pharmacological approaches of	409
biologics/monoclonal therapy in	344	Cell death	560
clinical manifestations of	340	TNF induced NF- B activation to control	560
diagnosis of	340	Cell death pathways	393
gastrointestinal manifestations in	342	Center nervous system	350
inhibitors of nucleotide synthesis for	343	apoptotic/inflammatory processes in	350
ocular manifestations in	340	Cetirizine	472,501,519
orogenital ulcers in	340	Chlorpheniramine	471,518
other therapies for	346	Chondroitin sulphate (CS)	221
pathogenesis of	339	anti-inflammatory effect of	229
pulmonary manifestation in	342	biological properties of	224
renal manifestations in	342	clinical studies of	229
therapy of	339,343	for treatment of osteoarthritis	221,226
use of acetazolamide in	346	pharmacokinetics of	227
use of azathioprine in	343	pharmacology of	227
use of colchicines in	345	rationale for use of	226
use of cyclosporine in	343	structure of	224
use of dapsone	346	Chronic inflammatory diseases	575
use of interferons in	344	CJ pollen allergens	194
use of methotrexate in	346	analysis of human T cell epitopes in	194
use of mycophenolate mofetil (MMF) in	343	DNA vaccine for	194,195
use of rebamipide in	346	Classic antihistamines	467
use of T cells inhibitors in	343	antiallergic effects of	468
use of tacrolimus in	344	as anti-inflammatory	468
use of thalidomide in	345	autonomic effect of	468
use of tumor necrosis factor- inhibitors in	345	CNS depression by	467
vascular involvement in	342	effects on cardiovascular system	468
Breast cancer	421	local anesthetic effect of	467
BRCA mutations in	424	non-specific effects of	467
complex genomic instability in	424	Clemastine	519
effect of DNA repair	421	Contact dermatitis	65
effect of genomic instability	421	agents used as inducers of experimental	67
role of telomeres	421	allergenic substances to induced	68
telomere fusions in	424	by allergenic natural products	70
telomere maintenance in	423	by medicinal plants	69
Cancer	353,575	cells implicated in	66
immunotherapy for	353	effects of natural products on	65
prime-boost strategies in	360	flavonoids against	73
self-replicating recombinant RNA in	360	<i>in vivo</i> protocols for	67
targeting strategies to dendritic cells in	361	inhibitors of	67
Cancer biology	422	mediators of	66
telomeres in	422	natural products as inducers of	68
Cartilage	221	natural products used against	70
function of	221	other compounds against	77
metabolism of	222	phenolics against	72
structure of	221	plant extracts against	70
Cartilage injury	265	study of	67
anti-catabolic treatment options in	267	terpenoids against	74
gene therapy approaches for	265	Coronary artery disease (CAD)	283
Caspases	562,598	antibacterial/antiviral therapy in	291
as executor of apoptosis	562	role of angiotensin converting enzyme (ACE)	
independent PCD processes	565	inhibitors in	287
		role of angiotensin receptor blockers (ARBs) in	287
		role of aspirin/salicylates in	290

role of cell adhesion molecules (CAMs) in	284	Diphenhydramine	518
role of chemokines in	285	DNA polymerase I-specific inhibitor	543
role of cytokines in	284	occurrence of	543
role of insulin/insulin sensitizers in	288	DNA vaccine	196
role of nuclear factor- κ B (NF- κ B) in	284	mechanism of	196
role of peroxisome proliferator-activated		Ebastine	473,503
receptors (PPARs) in	285	Endo-genous inhibitors of caspases	414
role of PPAR α in	286	therapeutic approaches targeting	414
role of PPAR β / δ in	287	Energy homeostasis	626
role of PPAR γ in	286	mechanisms involved in	626
role of statins/fibrates in	289	starvation response in	626
therapeutic targets of	287	Fever	628
Curcumin	547	Fexofenadine	474,502
anti-inflammatory activity of	547	Fibrocartilage	270
Cyclooxygenase 2 inhibitor	199	First generation (classic) antihistamines	466
cell cycle arrest by	202	Gene vaccines	353
COX-2 independent antitumor effects of	202	bacterial vector carriers for	355
future studies of	204	directed against tumor antigens	357
inhibition of activation of hepatic stellate cells by	200	in tumors	353
inhibition of liver fibrosis <i>in vivo</i>	201	plasmid DNA vectors for	354
mechanisms in growth inhibition of HCC by	202	role of dendritic cells	361
Cyproheptadine	471,518	viral vectors for	355
Cytokines	141,153,557	Glucosamine sulphate	217
in human	156	in osteoarthritis	217
in mice	156	preclinical research on	217
in tumor defense	158	safety of	219
production by T cells	153	H1 antihistamines	451,496
receptors for	557	activity at H ₁ receptors	496
regulation in autoimmune disease	158	development of	451
regulation in infectious diseases	156	drug-drug interactions of	455
regulation in pregnancy	157	effect of ethnicity	460
regulation of	153	effect of pharmacogenetics	460
soluble ligands of	141	effects of	497
TNF superfamily of	557	evaluation of	451
Danger-detector NKG2D	141	pharmacodynamics of	497
immunosurveillance of	141	pharmacokinetic considerations for efficacy of	455
modulation by	141	pharmacokinetics of	451,497
Death-receptor induced caspases	607	HAART	622
Dendritic cells (DC)	169	as model for bidirectional communic between	
effect of immunomodulatory drugs on	169	immunity/metabolism	622
effect of calcineurin inhibitors on	170	HCC cells	202
effect of mycophenolate mofetil (MMF) on	171	induction of cell apoptosis in	202
effect of rapamycin on	171	Hepatic stem cells	204
effect of retinoids on	172	role of COX-2/COX-2 inhibitors in	204
effect of thalidomide on	172	Hepatitis virus proteins	204
effect of vitamin D on	173	in COX-2 expression	204
regulation of function of	169	in hepato-carcinogenesis	204
Dermatologic disorders	485	role of	204
antihistamine use in	485	Hepatocellular carcinoma (HCC)	199
classic/first-generation H ₁ -type antihistamines in	485	anticancer drugs in treatment of	204
H ₂ -type antihistamines in	486	COX-2 inhibitors in angiogenesis of	204
low-sedating/second/third-generation		future studies of	204
H ₁ -type antihistamines in	485	role of COX-2 in	204
other agents use in	486	synergistic effect of COX-2 inhibitors for	204
Desloratadine	474,500,519		
Digestive tract	98		
inflammation in	98		
Dimetinden	518		

Histamine	82,495,637	role of PPARs in	631
and leukocyte penetration through vascular		to pathogens	177
endothelial cells	640	transcriptional control of	631
in autoimmune demyelinating disease of central		Immune system	349,625
nervous system	637	energy costs of	625
Histamine H1-antagonists	521	in ageing	349
carbon-linked alkylamine based	525	in cancer	349
first generation	521	in neurodegenerative diseases	349
nitrogen-linked ethylenediamines based	522	Immunity	619
oxygen-linked ethanolamines based	523	Infammatory responses	562
phenothiazines based	524	receptor shedding controls TNF -induced	562
piperazines based	522	Inflammation	560,619,631
piperidine based	525	adipokines in	619
second generation	526	immune response in	619
third generation	526	metabolism in	619
Histamine H-2 antagonists	526	regulation of	619
Histamine receptors	465,495,637	role of PPARs in	631
antiallergic effects of	467	TNF induced NF- B activation to controls	560
HIV infection	622	transcriptional control of	631
as model for bidirectional communic between		Inflammatory bowel disease (IBD)	297,319
immuity/metabolism	622	acetic acid induced colitis to study	299
Human 9 2 T cells	161	adalimumab for	322
specificities towards infected/cancer cells.....	161	adoptive transfer models for	300
structures of phosphoantigens of	162	animal models of experimental colitis for	298
phosphoantigen implication in.....	164	antagonists of TNF for.....	323
in recognition of cancer cells.....	164	anti-coagulation in	312
mode of activation by phosphoantigens	164	anti-ICAM-1 antibody for.....	326
Hydroxyzine	470,519	anti-IL-2 receptor antibody for	324
Hyperalgesia	335	anti-interferon antibody for.....	306,324
animal models for.....	335	anti-interleukin 12 (ABT-874) for.....	323
IL -1R-mediated signaling	22	anti- 4 integrin antibody (natalizumab) for	326
negative regulation of	23	anti- 7 integrin for	326
IL-1receptor associated kinases (IRAKs)	13	anti-TNF agents for.....	321
and Btk.....	16	basiliximab for.....	324
and MyD88s	16	biologic therapy of.....	319
and Pellinos 1/2/3	16	biologically targeted therapy for.....	301
and SIGIRR	16	C3H/HeJBir mice to study	299
and SOCS-1	16	CD45RB transfer model to study	300
and Tollip.....	15	CDP 571 (humicade) for.....	322
as new drug.....	18	CDP 870 for.....	322
as regulatory kinases.....	13	CNI-1493 for	323
as target for inflammatory diseases	18	colony sitmulating factors for.....	328
importance of.....	18	conjugated linoleic acid for.....	325
in infectious diseases	18	cotton-top tamarin colitis to study	300
in innate immunity.....	13	cytoprotection/repair in.....	327
IRAK-1	14	daclizumab (zenapax) for	324
IRAK-2	15	dextran sulfate sodium (DSS)-induced colitis	
IRAK-4	15	to study	299
IRAK-M.....	15	drug delivery to.....	312
molecules associated with	15	etanercept (enbel) for.....	323
regulates TIR signaling pathways.....	16	food additives/vitamins in.....	309
Immune regulation	637	genetically engineered models for	300
amino acid in	621	herbal medicine in.....	309
glucose in	621	HLA B27 transgenic rats to study	301
histamine in	637	IL-10 KO mice models to study	300
Immune response	177,621,631	IL-7 transgenic mice to study	301
in immune regulation	638	indomethacin-induced enterocolitis to study	299
lipid metabolism in	621	inducible colitis models for	299
		infliximab (remicade) for.....	321

inhibitors of inflammatory cytokines in.....	321	use of OX40/lymphotoxin receptors fusion proteins	302
inhibitors of lymphocyte tracking for	325	use of probiotics in.....	301
inhibitors of NF- κ B for	325	use of RDP58 in.....	305
iodoacetamide-induced colitis to study	299	use of selective NF- κ B inhibition in.....	307
knock out (KO) models for	300	use of soluble TNF- α receptor fusion proteins in....	302
leflunomide for.....	325	use of T-cell surface membrane protein	307
miscellaneous therapies for.....	328	use of TNF- α inhibitors in.....	302
novel therapy of	319	use of transcription factors inhibitors in	307
OPC-6535 for.....	328	use of α 1/ β 7/ α 2/ α 4 β 1 integrins/P-selectin glycoprotein ligand-1 antibodies in	307
other treatment modalities for	312	use of α 4 integrin antibody (natalizumab) in	306
oxazolone-induced colitis to study	299	use of α 4 β 7 integrin antibody (MLN-02 or LDP-02)	307
p55 TNF receptor (onerecept) for.....	323	visilizumab (nuvion) for	324
peptidoglycan-polysaccharide (PG-PS)-induced colitis to study	299	Inflammatory diseases	99
peroxisome proliferator-activated receptor (PPAR- γ) ligands in	309	scintigraphy in.....	99
pro-apoptotic agents for	324	Inflammatory disorders	587
recombinant human IL-10 for.....	324	4-1BB in	593
role of antisense oligonucleotide to ICAM-1 (Isis 2302) in	307	BLYS in	592
role of epidermal growth factor (EGF) in	327	CD40L in	592
role of experimental animal models in.....	297	FAS in	593
role of human growth hormone in.....	327	OX40 in	593
role of IL-11 (rh IL-11) in.....	327	TNF-alpha in	588
role of keratinocyte growth factor-2(KGF-2, repifermin) in	327	Inhibitor of apoptosis proteins (IAPs)	393
role of PPAR agonists in.....	325	antagonists of	393,397
role of tumor necrosis factor (TNF) in.....	321	BIR-containing proteins in	394,396
rosiglitazone for	325	in cancer therapy	401
SAMP1/Yit mice to study	300	levels of	399
signal transducer/activating transcription (STAT)-4 transgenic mice to study.....	301	mechanism of caspase inhibition by	397
sodium butyrate for	325,326	role in cancer	393
spontaneous colitis models for	299	role in neurological disease	393,402
T cell receptor (TCR) mutant mice to study	300	structural studies of	397
thalidomide for.....	323	Innate immune receptors	29
TNF-3' untranslated region (UTR) KO mice to study	300	and IRF family transcription factors	29
toll-like receptor (TLR) signaling in.....	327	Interferon (IFN- γ).....	121
transgenic mouse/rat models to study	301	assays for secretion of	122
treatment of	297	assays in body fluids for.....	124
treatment strategies for.....	301	assays in cellular supernatants for.....	124
trefoil factor-deficient mice to study	300	detection in tissues secretion	124
trefoil factors (TFF) in	327	detection of.....	121
tri-/di-nitrobenzene sulfonic acid (TNBS/ DNBS)-induced colitis to study	299	prevention of release of.....	121
use of adhesion molecule inhibitors in.....	306	single-cell assays for	125
use of adhesion molecules antibodies in	307	strategies for inhibition of secretion of.....	127
use of anti-inflammatory cytokines in	306	Interferon regulatory factor (IRF).....	29
use of anti-oxidants in.....	310	IRF-3 as.....	29
use of anti-TNF- α antibodies in.....	302	IRF-7 as.....	29
use of growth factors in.....	309	signal transduction by TLR7/TLR8	31
use of IkappaB kinase (IKK) inhibitor in	309	Interleukin-1	133
use of IL-10/IL-11/TGF- β 1 in	306	control of	133
use of inflammatory cytokines inhibitors in	302	externalization by lysosome exocytosis	137
use of inhibitors of IL-12/IL-16/IL-18.....	305	externalization by vesiculation.....	134
use of inhibitors of IL-6 receptor (IL-6R) in.....	306	mechanism secretion in human monocytes.....	135
use of other cytokine inhibitors in.....	305	mechanisms of non classical secretion of.....	133
		polarized secretion by dendritic cells	137
		secretion in immune response	133
		secretion in inflammation.....	133
		therapeutic approaches to control activity of	138

translocation of	135	Liver fibrosis.....	199
IRAK family	14	and products of COX-2.....	201
functional analysis of.....	14	COX-2 expression in	199
IRAK-1	14	COX-2 inhibitors in	199
IRAK-2	15	future studies of	204
IRAK-4	15	inhibition of growth signaling pathway in.....	203
IRAK-M.....	15	relationship between COX-2 and TGF- 1 in	202
structure of	14	significance of COX-2 in.....	199
IRF-3	29	Localized peripheral/central inflammation.....	335
activation by TLR3 stimulation.....	30	animal models for	335
activation by TLR4 stimulation.....	30	Loratadine	472,499,519
and role of regulatory protein kinases	30	Metabolic regulation	617
and role of TBK-1/IKK-1	30	Metabolism	223,631
signal transduction by TLR7/TLR8.....	31	control of.....	223
IRF-7	29	role of PPARs in	631
and role of regulatory protein kinases	30	transcriptional control of	631
and role of TBK-1/IKK-1	30	Mitochondria	439
Islet cell proinflammatory chemokine production	649	effect of heat shock	443
downregulation of	649	effect of hyperoxia	443
Isoprenoid metabolic pathways.....	162	effect of hypoxia	443
Japanese cedar pollinosis	193	effect of ionizing radiation	443
development for	193	function of	439
immunotherapies for	193	genome of	441
peptide vaccine in.....	193	in age-related disease	444
JNK MAPK pathway	571	in aging	444
NF- B-inducible effectors in	571	in cancer	439,445
pro-apoptotic role of	571	in cell death	441
role of ferritin heavy chain	574	in immune system	439,445
role of Mn-SOD	574	in programmed cell death	439
role of reactive oxygen species (ROS)	573	metabolism of	440
Ketotifen	473	origin of	439
Leptin	619,627	physiology of	439
and melanocortin axis.....	627	structure of	439,440
Leukocyte adhesion molecule DNAM-1 (CD226).....	53	targeting in gene therapy	446
and LFA-1.....	55	Mitotoxicity	439
as two-sword fencer.....	53	toxicity of	439
cytokine secretion by.....	55	Mitotxins	442
for adaptive immunity	53	drugs as	442
for innate immunity	53	Mizolastine	473,503
identification of ligands for	54	Multiple sclerosis	373
identification of novel.....	53	MyD88-independent/TRIF-dependent pathway.....	7
in activation/adhesion of platelets	56	Myeloid-related proteins	383
in CD4 ⁺ naïve T cell differentiation/proliferation	55	S100A8 as	383
in cytotoxicity of.....	55	S100A9 as	383
in LFA-1-mediated costimulatory signals	55	Natural killer (NK) cells.....	115
in Nk cell/antigen specific T cell-mediated		activating receptor (AR) of.....	115
cytotoxicities.....	54	apoptosis without affecting cytolytic activity in	118
role in macrophage migration/infiltration.....	56	CD8-mediated apoptosis in	117
signal transduction mediated by	56	down-regulation by cyclosporin A in.....	119
Levocetirizine	472,501	effect of activating isoforms of KIR/CLIR (AR)	118
Liver cancer	199	effect of cyclosporin.....	118
COX-2 inhibitors in	199	engagement of CD8-/AR in.....	119
future studies of.....	204	inhibiting receptors (IRS) of.....	115
inhibition of growth signaling pathway in	203	interaction with CD8	116
relationship between COX-2 and TGF- 1 in.....	202	pro-inflammatory cytokines in	115
significance of COX-2 in	199	regulation by cyclosporin A	115
		shLA-I molecules deliver apoptotic signal in.....	118

soluble HLA-I induced apoptosis in.....	116	unusual cytokine production by	59
soluble HLA-I triggers IFN- release in	119	NKT cell-mediated protective functions	60
triggering of apoptosis in.....	115	cellular/molecular mechanisms of.....	60
Neurodegenerative diseases	368	NOD2	43
Alzheimer's disease as	368	function of	43
amyotrophic lateral sclerosis as	371	molecular structure of.....	43
cellular approaches to target	374	Non-TLR innate pathogen receptors	31
Huntington's disease as	371	activation of IRF-3/cytokine production by	31
immunological approaches to target	371	Nucleotide-oligomerization domains (NODs) proteins.....	43
multiple sclerosis as	371	associated diseases of	43
non immunological approaches to target	375	gain-of-function mutation of	47
Parkinson's disease as	370	human diseases due to	47
Neuroendocrine-immune interface	627	loss-of-function type mutations of	47
Neuro-hormonal regulation	625	molecular functions of.....	43
leptin in	627	perspective/direction for future study of	48
melanocyte stimulating hormone in	627	role in immune responses	45
of immune/metabolic function	625	Oral antihistamines	495
role of hypothalamic-pituitary-adrenal axis	628	in pediatrics	495
Neuronal apoptosis	367	in treatment of allergic diseases	498
during neuroinflammation	367	safety of	495
immunological approaches to prevent	367	Osteoarthritic knees	213
New antihistamines	465	non-surgical treatment of.....	212
NF- B	569	surgical treatment for	213
effect on A20	573	Osteoarthritis	209,217,221,235,265
effect on gadd45b	573	adeno-associated virus-based vectors in	274
effect on XIAP	573	adenoviral vectors in	272
indirect targeting of JNK pathway by	573	anabolism in	268
inducible effectors targeting JNK pathway	572	anabolic responses in	268
inhibition of apoptosis by	570	animal experiments of	275
mediated control of apoptosis induced by		antibody against IL-1 in	239
TNF-RS	570	anti-catabolic treatment options in	266
to targets JNK signaling cascade	569	anti-inflammatory cytokines in	239
NK cells	145	articular cartilage in.....	209
innate interactions of	145	basic fibroblast growth factor in	244
NK receptors	142	blocking COX/leukotriene pathways in	240
activating type.....	142	blocking inducible NO in	240
inhibitory type.....	142	BMPs in	243
NKG2D	145	catabolic factors in.....	238
and autoimmunity	149	CDMPs in	243
and cytokines	148	chondroprotection in	269
and cytomegalovirus	146	connective tissue growth factor in	244
and tumor immunosurveillance	147	control of chondrocyte phenotype in	271
autoimmunity linked to.....	149	cytokines in.....	235
in infection	149	development of.....	210
mediated immunosurveillance by soluble		diagnosis of.....	211
NKG2DL	148	disease modifying drugs in.....	235
signaling of	145	eicosanoids in	237
NKG2D ligands	143	endogenous repair in	269
expression of.....	144	endothelin-1 in.....	238
of man	143	enhanced catabolism in	265
of mouse	143	gene therapy approaches for	265
NKT cell.....	59	growth factors in	235,244
as auto-reactive repertoire	59	growth factors in treatment of	242
as regulator in acquired immunity	59	hepatocyte growth factor in	244
as regulator in innate immunity	59	Herpes simplex virus-based vectors in	274
dynamism of phenotype/function following		IL-1 converting enzyme in	239
activation of	60	IL-1Ra in	239
mediated immune regulation	61	induction of chondrogenesis in	270
mediated pathogenic responses	60		

inflammatory components of.....	235	PTX B-oligomer (PTX-B).....	177
inhibiting inflammatory processes in	239	adjuvant properties of.....	179
insulin-like growth factors in	243	anti-viral activities of.....	177
intracellular pathway in	240	immunomodulatory activities of	177
neuropeptides in.....	238	mediated control of viral infections.....	180
nitric oxide in.....	237	modulation of autoimmune responses by	179
non-surgical treatment of.....	212	Reactive oxygen species (ROS)	442
non-viral vectors in	274	Receptor interacting protein-2(Rip2).....	35
other inflammatory factors in	237	functional properties of	36
pathobiology of.....	223	future of	40
peroxisome proliferator-activated receptor		in acquired immunity.....	39
gamma in.....	240	in innate immunity.....	38
pharmacological treatment of	224	to regulate acquired immunity.....	35
preclinical research on	217	to regulate innate immunity.....	35
pro-inflammatory cytokines in	236,238	Rheumatoid arthritis	335,587
protection of repair tissue in	272	4-1BB in	593
protein delivery vs. gene transfer in	272	animal models for.....	335
retroviral vectors in	274	BLYS in	592
risks of	211	CD40L in	592
soluble IL-1R in.....	238	FAS in	593
soluble IL-1RAcP in.....	239	OX40 in	593
structural effects in	218	TNF-alpha in	588
structure modification in.....	217	RIP	563
surgical treatment for.....	213	as mediator of cell survival	563
symptomatic effects in.....	218	programmed necrosis by	563
symptoms of	217	Rip gene family	36
TGF- super-family in	242	Rupatadine	474
therapeutic strategy of	275	S100A8/A9.....	383
therapeutic targets of	238,244	apoptosis-inducing activity of	386
to improve cartilage repair in	270	by cellular activation	383
treatment of.....	235	cell surface binding site for	388
vectors for intraarticular gene transfer in	272	cellular functions of	385
		effect of antioxidants	387
Peroxisome proliferator-activated receptors (PPARs)	631	effect of zinc	386
expression in immune/inflammatory cell	632	from inflammatory cells	383
in atherosclerosis	633	phases of apoptosis/inducing activity of	388
in immune system	632	Second generation antihistamines	471
in inflammation	633	Second generation H1 antihist amines	452
in insulin resistance	633	cardiac safety of	457
in obesity	633	effect of ethnicity	460
in type 2 diabetes	633	effect of pharmacogenetics	460
use of genetically modified rodent models to		pharmacokinetic considerations in safety of	457
study	632	pharmacokinetic properties of	452
Pertussis toxin	177	sedation by	459
adjuvant properties of.....	179	Secretory lysosome.....	135
anti-viral activities of.....	177	in immuno inflammation	135
immunomodulatory activities of.....	177	SIGIRR/TIR8.....	21
mediated control of viral infections.....	180	as negative regulator of Toll-IL-1R signaling.....	21
modulation of autoimmune responses by	179	Signaling.....	31
non-toxic derivatives of.....	177	by TLR9	31
Pheniramine	519	by IRF-8	31
Phenothiazines	519	Somatostatin	91
Programmed cell death (PCD)	569	agonists/antagonists of	93
Programmed necrosis	562	analogs of	94
anti-viral mechanism of	563	antisecretory activity of.....	100
as inducer of inflammation	562	cell growth arrested by	100
TNFR-2 sensitizes cells to	563	clinical/experimental/molecular aspects of	96
PT-9K/129G.....	180		
mediated control of viral infections	180		

expression in immune cell system.....	98	21- <i>O</i> -Tetradecanoylphorbol-13-acetate (TPA)	543
expression in inflamed organs	96	effect of inhibition of DNA polymerase I	
in granulomas	97	suppression	543
in Graves ophtalmopathy.....	97	induced inflammation	543
in inflammatory chronic diseases	91,96	TH1 polarization.....	323
in local experimental inflammation.....	98	inhibitors of.....	323
in peripheral blood immune cells	99	Thiazolidinediones (TZDs)	531
in sarcoidosis	97	as novel anti-inflammatory drugs	531
in spleen.....	98	implication for	531
in thymus	98	in Alzheimer's disease	535
induction of apoptosis by.....	100	in arthritis	537
inhibition of angiogenesis by.....	101	in atherogenesis	532
inhibition of cell proliferation by.....	100	in atherosclerosis	532
intra-cellular pathways of.....	100	in atopic dermatitis	536
mechanisms of actions of	100	in dermatitis	536
novel therapeutic targets for	91	in dermatosis	536
regulation of cell migration by	101	in endometriosis	538
structure-activity relationships of	93	in inflammatory bowel disease (IBD)	536
Somatostatin analogs	95	in inflammatory diseases	532
binding profile of.....	95	in multiple sclerosis	535
clinical use of.....	95	in neurological diseases	535
in granulomas	97	in non-alcoholic steatohepatitis	538
in Graves ophtalmopathy.....	97	in other neuroinflammatory diseases	536
in local experimental inflammation.....	98	in post-traumatic cystic cavitation	536
in sarcoidosis	97	in psoriasis	536
selective receptor subtype of	95	in renal diseases	537
side effects of.....	95	in respiratory diseases	532
Somatostatin receptors	91	in sepsis	538
clinical/experimental/molecular aspects of.....	96	mechanisms of	532
expression in immune cell system.....	98	side effects of	539
expression in inflamed organs	96	Third generation antihistamines	474
in granulomas	97	Thymulin	333
in Graves ophtalmopathy.....	97	and inflammatory mediators.....	334
in inflammatory diseases	96	anti-inflammatory actions of	334
in local experimental inflammation.....	98	as anti-inflammatory molecule.....	333
in peripheral blood immune cells	99	in diseases.....	333
in sarcoidosis	97	in inflammation	333
in spleen.....	98	role in disease modulation.....	334
in thymus	98	role in neuro-immune-endocrine interactions	333
Stress	628	TLR-mediated MyD88-independent signaling pathway	23
Systemic antihistamines	521	TNF-receptor	597
adverse cutaneous reactions of	521	induced apoptosis	597
T cell.....	165,153	inflammation by	597
cytokine release by	155	inhibition of associated factors of	606
general function of.....	155	viral inhibition interaction of	602
immuno intervention with synthetic		viral inhibition of	602
phosphoantigens	165	viral inhibition of apoptosis function by	606
ligands of human	154	viral inhibition of expression of	605
ligands of murine	154	viral inhibition of mediated inflammation by	608
repertoire of		Tnfrsf1A mutants	582
significance of.....	165	relationships between molecular abnormalities	
Th1/Th2 pattern of.....	156	of	582
T cell epitope peptide.....	195	TNF signaling	557
using invariant chain gene for	195	signaling complexes that mediate	559
TACE	602	TNF /TNF-receptors	598
viral subversion of	602	effect on JNK signaling	598
Terefindine	473,519	effect on MAPK	598
		effect on NFkB	598
		in cell death	598

in inflammations	598	Topical antihistamines	479
TNF-TNFR superfamily	587	Tumor necrosis factor (TNF)	557
in pathogenesis/treatment of inflammatory		in cell death	557
diseases	587	in inflammation	557
in pathogenesis/treatment of rheumatoid		Tumor necrosis factor receptor associated periodic	
arthritis	587	syndrome (TRAPS)	577
Toll-IL -1R superfamily	21	clinical/genetic characterization of	577
immunoglobulin (I _g) domain subgroup of	21	effects of mutations on behaviour of	
leucine rich repeat motif (LRR) subgroup of	22	TNFRSF1A by	580
SIGIRR	23	therapy in	583
and ST2	24	TNF in	577
other negative regulators of	24	TNF receptors in	577
Toll-like receptors (TLRs)	3,21,29	Tumour necrosis factor-	597
adaptors of	3	anti-viral effects of	601
and role of TIR domain-containing adaptors	8	complexities/biology of	601
and TIRAP/Mal	6	viral inhibition of	597,602
future prospects of	9	viral inhibition interaction of	602
in innate immunity	3	viral subversion of	602
microbial recognition by	3	V 9/V 2 T lymphocytes	161
MyD88 as domain of	6	mechanism of actions of	161
MyD88- dependent pathway of	6	non peptide antigens activating human type	161
regulation of signaling of	8	use for immunointervention	161
signaling pathways of	5	Vaccines	185
subcellular localization of	5	emulsion adjuvants for	188
TLR1 as	3	microencapsulated antigens for	189
TLR2 as	3	novel adjuvants for	185,186
TLR3 as	4	water-soluble adjuvants for	187
TLR4 as	4	Vitamin D receptor (VDR)	645
TLR5 as	5	as immuno/regulatory agents	645
TLR6 as	3	immunomodulatory effects of	646
TLR7 as	5	in autoimmune disease models	646
TLR8 as	5	in inhibiting T1D development	646
TLR9 as	5	inhibition of type 1 diabetes development by	645
TLR11 as	5		
TRAM as adaptor of	8		
TRIF as adaptor of	7		